<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="biomedicines-08-00060-t002" orientation="portrait" position="float">
 <object-id pub-id-type="pii">biomedicines-08-00060-t002_Table 2</object-id>
 <label>Table 2</label>
 <caption>
  <p>Clinical trials of melanoma treatment using oncolytic viruses.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trial</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Results</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-1</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved durable response rate (16.3% vs. 2.1%), overall response rate (26.4% vs. 5.7%) and longer median survival (patients with non-surgically resectable melanoma) [
     <xref rid="B116-biomedicines-08-00060" ref-type="bibr">116</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B116-biomedicines-08-00060" ref-type="bibr">116</xref>,
     <xref rid="B117-biomedicines-08-00060" ref-type="bibr">117</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-1</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase Ib/II</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50% objective response rate
     <break/>44% of patients had a durable response lasting &gt;6 months
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B118-biomedicines-08-00060" ref-type="bibr">118</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV T-VEC</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II/IIIb</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overall survival superior for patients with stage III and IV M1a melanoma
     <break/>Significant clinical benefits in phase III
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B114-biomedicines-08-00060" ref-type="bibr">114</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reovirus</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No objective responses seen</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B73-biomedicines-08-00060" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coxsackievirus</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase Ib</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stable disease in 26.7% of patients
     <break/>Best ORR of 60%
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B119-biomedicines-08-00060" ref-type="bibr">119</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coxsackievirus</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Durable responses in melanoma metastases (injected and uninjected)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B116-biomedicines-08-00060" ref-type="bibr">116</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Newcastle Disease Virus</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II/III</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No superiority compared to controls</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B120-biomedicines-08-00060" ref-type="bibr">120</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alphaviruses</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10-fold enhanced IL-12 plasma levels
     <break/>Encapsulation enhanced tumor targeting
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B121-biomedicines-08-00060" ref-type="bibr">121</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
